Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16849098 | 0.73 | — | — | |
| SCHEMBL2642449 | 0.72 | HTR2B (0.45) | LOXL2LMNARAB9A | |
| SCHEMBL3597949 | 0.68 | MMP1 (0.53) | LOXL2ALDH1A1L3MBTL1 | |
| SCHEMBL11116625 | 0.68 | CDC7 (0.49) | SMN1; SMN2LMNARAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL23120712 | 0.67 | MMP1 (0.51) | LOXL2ALDH1A1L3MBTL1 | |
| SCHEMBL9926020 | 0.67 | MAPT (0.51) | ALDH1A1RAB9AMEN1 | |
| SCHEMBL7983789 | 0.64 | LOXL2 (0.36) | LOXL2MEN1 | |
| SCHEMBL20558119 | 0.64 | CDK5 (0.45) | LOXL2 | |
| SCHEMBL2642531 | 0.64 | MAPT (0.38) | LOXL2ALDH1A1RAB9AMEN1 | |
| SCHEMBL1468212 | 0.64 | ALDH1A1 (0.37) | LOXL2ALDH1A1LMNARAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190832-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | ABBOTT GMBH & CO. KG (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20110071285-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | ABBOTT GMBH & CO. KG (DE) | 2011-03-24 | — | — | US | disclosed |
| US-7144902-B1 | Prodrugs of thrombin inhibitors | ABBOTT GMBH & CO. KG (DE) | 2006-12-05 | — | — | US | disclosed |
| EP-1169338-B1 | LOW-MOLECULAR INHIBITORS OF COMPLEMENT PROTEASES | ABBOTT GMBH & CO KG (DE) | 2004-11-03 | — | — | EP | disclosed |
| EP-0956294-B1 | THROMBIN INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-6740647-B1 | AMIDINES AND HYDROXYAMIDINE DERIVATIVES | ABBOTT GMBH & CO., KG (DE) | 2004-05-25 | — | — | US | disclosed |
| US-20040048815-A1 | Low-molecular serine proteases inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals | ABBOTT GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
| US-6683055-B1 | GUANIDINE OR AMIDINE TERMINED PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-27 | — | — | US | disclosed |
| EP-1370573-A2 | LOW MOLECULAR SERINE PROTEASE INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | Abbott GmbH & Co. KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002030940-A2 | LOW MOLECULAR SERINE PROTEASE INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | ABBOTT GMBH & CO. KG (DE) | 2002-04-18 | — | — | WO | disclosed |
| EP-1169338-A2 | LOW-MOLECULAR INHIBITORS OF COMPLEMENT PROTEASES | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-09 | — | — | EP | disclosed |
| EP-1165601-A2 | PRODRUGS OF THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-02 | — | — | EP | disclosed |
| EP-1051431-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000061609-A2 | PRODRUGS OF THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000061608-A2 | LOW-MOLECULAR INHIBITORS OF COMPLEMENT PROTEASES | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
| US-6114358-A | Thrombin inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | disclosed |
| EP-0956294-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-17 | — | — | EP | disclosed |
| WO-1999037668-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-29 | — | — | WO | disclosed |
| WO-1998006741-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071285-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | F2R, C1R, PRSS1 | LOXL2 2688/4885ALDH1A1 2835/4885SMN1; SMN2 4412/4885 |
| US-20040048815-A1 | Low-molecular serine proteases inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals | F2R, C1R, PRSS1 | LOXL2 2335/4885ALDH1A1 2866/4885SMN1; SMN2 4615/4885 |
| US-20120190832-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | F2R, C1R, PRSS1 | LOXL2 2688/4885ALDH1A1 2835/4885SMN1; SMN2 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.